RxDoctor Payments Data

Henry Cheng, MD

Family Medicine · Anaheim, CANPI 1811276181

Payments from drug & device makers

$15,482in general payments, 2019–2025

Across 363 payments — averaging $42.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Teva Pharmaceuticals USA, Inc.$893
  • GSK$738
  • Pfizer$624
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$15,451100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,482 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$51,246
Medicare patients
220
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide48$61,504
JardianceEmpagliflozin54$51,382
OzempicSemaglutide29$44,070
EliquisApixaban62$36,661
Repatha SureclickEvolocumab44$33,559
XareltoRivaroxaban31$33,027
JanuviaSitagliptin Phosphate42$29,536
TrulicityDulaglutide15$21,409
FarxigaDapagliflozin Propanediol21$17,923
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,752
MounjaroTirzepatide13$12,781
Breo ElliptaFluticasone/Vilanterol14$5,606
VyvanseLisdexamfetamine Dimesylate13$4,898
Testosterone14$2,995
Atorvastatin Calcium396$2,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,643$105,57477 claims
Boehringer IngelheimJardiance$273$51,38254 claims
PfizerEliquis$624$36,66162 claims
Lilly USA, LLCTrulicity, Mounjaro$368$34,19028 claims
Johnson & JohnsonXarelto$332$33,02731 claims
MerckJanuvia$14$29,53642 claims
GSKTrelegy Ellipta, Breo Ellipta$738$21,35834 claims
AstraZenecaFarxiga$2,455$17,92321 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$12$4,89813 claims
AbbVieSynthroid, Armour Thyroid$399$2,11244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →